Therefore, antitumor therapies that antagonize CTLA‐4 and/or PD‐1/PD‐L1 can attenuate the immune escape signal released by the tumor and enhance the host antitumor immune response.380, 381, 382. The gene discussed is CTLA4; the disease is neoplasm.